Literature DB >> 23324579

ADAM 12: a putative marker of oligodendrogliomas?

Dimitrios Kanakis1, Uwe Lendeckel, Paraskevi Theodosiou, Henrik Dobrowolny, Christian Mawrin, Gerburg Keilhoff, Alicia Bukowska, Knut Dietzmann, Bernhard Bogerts, Hans-Gert Bernstein.   

Abstract

ADAM 12 (meltrin alpha) belongs to a large family of molecules, consisting of members with both disintegrin and metalloproteinase properties. ADAMs have been implicated in several cell physiological processes including cell adhesion, cell fusion, proteolysis and signalling. ADAM 12 is widely expressed, including skeletal muscle, testis, bone, intestine, heart and kidney. In addition, a variety of tumours show elevated expression of ADAM12; among them being breast-, colon-, gastric- and lung-carcinoma. As to the brain, ADAM 12 has been shown previously to be expressed in rat and human oligodendrocytes. However, little is known about the expression of this protease in brain tumours. This study demonstrates the presence of ADAM 12 in non-neoplastic oligodendroglial cells of normal human brain as well as in neoplastic oligodendroglia and minigemistocytes arising from four pure oligodendrogliomas and three mixed oligoastrocytomas. Double stainings revealed a notable preference of ADAM 12 for the oligodendroglial over astroglial components. The results of immunohistochemistry are in accordance with the results obtained from the RT-PCR, which further demonstrated a mild difference concerning the mRNA concentration of ADAM 12 between similar grades of eight astrocytomas and eight oligodendrogliomas (namely four astrocytomas grade II versus four oligodendrogliomas grade II and four astrocytomas grade III versus four oligodendrogliomas grade III). Both cellular immunostaining for ADAM 12 and ADAM 12 mRNA content decrease with higher histologic grade of the tumour. Surprisingly, the latter parameter (ADAM12 mRNA) showed a significant opposite correlation to the degree of histologic tumour malignancy. From our data showing that ADAM 12 is highly expressed in, but not restricted to, oligodendrogliomas, we conclude that ADAM 12 immunohistochemistry may be a helpful tool in the diagnosis of brain tumours.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23324579      PMCID: PMC3810230          DOI: 10.3233/DMA-120953

Source DB:  PubMed          Journal:  Dis Markers        ISSN: 0278-0240            Impact factor:   3.434


  5 in total

Review 1.  A disintegrin and metalloproteinase-12 (ADAM12): function, roles in disease progression, and clinical implications.

Authors:  Erin K Nyren-Erickson; Justin M Jones; D K Srivastava; Sanku Mallik
Journal:  Biochim Biophys Acta       Date:  2013-05-13

Review 2.  Advances in urinary protein biomarkers for urogenital and non-urogenital pathologies.

Authors:  Johanna Pedroza-Díaz; Sarah Röthlisberger
Journal:  Biochem Med (Zagreb)       Date:  2015       Impact factor: 2.313

3.  CLCA2 as a novel immunohistochemical marker for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the lung.

Authors:  Kazuya Shinmura; Hisaki Igarashi; Hisami Kato; Yuichi Kawanishi; Yusuke Inoue; Satoki Nakamura; Hiroshi Ogawa; Takashi Yamashita; Akikazu Kawase; Kazuhito Funai; Haruhiko Sugimura
Journal:  Dis Markers       Date:  2014-12-07       Impact factor: 3.434

Review 4.  Tumor Microenvironment in Glioma Invasion.

Authors:  Sho Tamai; Toshiya Ichinose; Taishi Tsutsui; Shingo Tanaka; Farida Garaeva; Hemragul Sabit; Mitsutoshi Nakada
Journal:  Brain Sci       Date:  2022-04-15

5.  Urinary concentrations of ADAM 12 from breast cancer patients pre- and post-surgery vs. cancer-free controls: a clinical study for biomarker validation.

Authors:  Erin K Nyren-Erickson; Michael Bouton; Mihir Raval; Jessica Totzauer; Sanku Mallik; Neville Alberto
Journal:  J Negat Results Biomed       Date:  2014-04-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.